Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB–IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study

Journal:

The Lancet Oncology

Published:

2026-02-13

DOI:

10.1016/s1470-2045(25)00709-0

Affiliations:

34

Authors:

25

Go to article

Institutions	Authors	Share
Merck & Co, United States of America (USA)	3.000000	0.12
University Hospital Zurich (UHZ), Switzerland	1.000000	0.04
Beijing Cancer Hospital / School of Oncology, PKUHSC, China	1.000000	0.04
University of Pittsburgh Medical Center (UPMC), United States of America (USA)	1.000000	0.04
University Medical Center Schleswig-Holstein - Campus Kiel (UKSH Kiel), Germany	1.000000	0.04
Yonsei Cancer Hospital, South Korea	1.000000	0.04
Maria Sklodowska-Curie National Research Institute of Oncology, Poland	1.000000	0.04
Fudan University Shanghai Cancer Center (FUSCC), China	1.000000	0.04
Wuhan Union Hospital, HUST, China	1.000000	0.04
Cape Town Oncology Trials, South Africa	1.000000	0.04
UCLA Jonsson Comprehensive Cancer Center, United States of America (USA)	1.000000	0.04
Onkologikoa, Spain	1.000000	0.04
Rabin Medical Center (RMC), TAU, Israel	1.000000	0.04
Hospital Maternidade São Vicente de Paulo, Brazil	1.000000	0.04
Hacettepe University, Turkey	1.000000	0.04
Fundación Arturo López Pérez (FALP), Chile	1.000000	0.04
Essen University Hospital, Germany	0.666667	0.03
Melanoma Institute Australia, Australia	0.583333	0.02
Hollywood Private Hospital, Australia	0.500000	0.02
Edith Cowan University (ECU), Australia	0.500000	0.02
IRCCS Istituto Nazionale Tumori IRCCS-Fondazione G. Pascale, Italy	0.500000	0.02
University of Naples Federico II (UNINA), Italy	0.500000	0.02
Fujian Cancer Hospital, China	0.500000	0.02
Fuzhou University (FZU), China	0.500000	0.02
Harbour Cancer and Wellness, New Zealand	0.500000	0.02
The University of Auckland, New Zealand	0.500000	0.02
Westmead Hospital (WSLHD), Australia	0.333333	0.01
Blacktown and Mount Druitt Hospital (BMDH), Australia	0.333333	0.01
DKTK Partner Site Essen/Düsseldorf, Germany	0.333333	0.01
The University of Sydney (USYD), Australia	0.250000	0.01
Royal North Shore Hospital (RNSH), Australia	0.250000	0.01
Mater Hospital North Sydney, Australia	0.250000	0.01

Interested in Oncology and Carcinogenesis?